Bioxytran (BIXT) director adds preferred and common shares

Rhea-AI Filing Summary

Bioxytran, Inc. (BIXT) reported insider share purchases by director Alan Hoberman. On 08/12/2025, he acquired 10,417 shares of preferred stock at $0.485 per share, bringing his preferred holdings to 377,619 shares. On 11/14/2025, he bought an additional 38,588 preferred shares at $0.35 per share, increasing his total preferred holdings to 416,207 shares. On 11/18/2025, he purchased 210,000 shares of common stock at $0.60 per share and held 210,000 common shares afterward. All positions are reported as held directly by the insider.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoberman Alan M

(Last) (First) (Middle)

6134 MECHANICSVILLE ROAD

PO BOX 56

(Street)

MECHANICSVILLE PA 18934

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOXYTRAN, INC [ BIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
preferred	08/12/2025		A		10,417	A	$0.485	377,619	D
preferred	11/14/2025		A		38,588	A	$0.35	416,207	D
common	11/18/2025		P		210,000	A	$0.6	210,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Alan Hoberman	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for BIOXYTRAN, INC (BIXT)?

The filing reports that director Alan Hoberman acquired preferred shares on 08/12/2025 and 11/14/2025, and common shares on 11/18/2025, all in open-market style purchases.

How many BIOXYTRAN (BIXT) preferred shares did the director acquire and at what prices?

On 08/12/2025, the director acquired 10,417 preferred shares at $0.485 per share. On 11/14/2025, he acquired 38,588 preferred shares at $0.35 per share.

What are the director’s total preferred share holdings in BIOXYTRAN (BIXT) after these transactions?

After the 08/12/2025 preferred share purchase, the director held 377,619 preferred shares. Following the 11/14/2025 transaction, his preferred holdings increased to 416,207 shares.

How many BIOXYTRAN (BIXT) common shares did the director purchase?

On 11/18/2025, the director purchased 210,000 shares of BIOXYTRAN common stock at a price of $0.60 per share.

What is the director’s ownership form for the reported BIOXYTRAN (BIXT) shares?

The filing indicates that the director’s holdings of both preferred and common BIOXYTRAN shares are owned in direct form.

What is the relationship of the reporting person to BIOXYTRAN, INC (BIXT)?

The reporting person, Alan Hoberman, is identified as a director of BIOXYTRAN, INC.